Product wastage from modern human growth hormone administration devices: a laboratory and computer simulation analysis

• Main Authors: Pollock RF, Qian Y, Wisniewski T, Seitz L, Kappelgaard AM
• Format: Article
• Language: English
• Published: Dove Medical Press 2013-08-01
• Series: Medical Devices : Evidence and Research
• Online Access: http://www.dovepress.com/product-wastage-from-modern-human-growth-hormone-administration-device-a13875

Richard F Pollock,1 Yujun Qian,2 Tami Wisniewski,3 Lisa Seitz,4 Anne-Marie Kappelgaard2 1Ossian Health Economics and Communications GmbH, Basel, Switzerland; 2Novo Nordisk AS, Bagsv&aelig;rd, Denmark; 3Novo Nordisk Inc, Princeton, NJ, USA; 4Novo Nordisk Pharma GmbH, Mainz, Germany Background: Treatment of growth hormone disorders typically involves daily injections of human growth hormone (GH) over many years, incurring substantial costs. We assessed the extent of undesired GH loss due to leakage in the course of pen preparation prior to injection, and differences between the prescribed dose, based on patient weight, and the actual delivered dose based on pen dosing increments in five GH administration devices. Methods: Norditropin&reg; prefilled FlexPro&reg;, NordiFlex&reg;, NordiLet&reg;, and durable NordiPen&reg;/SimpleXx&reg; 5 mg pens (Novo Nordisk A/S, Bagsv&aelig;rd, Denmark) and durable Omnitrope&reg; Pen-5 devices (Sandoz, Holzkirchen, Germany) were tested (n = 40 for each device type). Product wastage was measured in accordance with validated protocols in an ISO (International Organization for Standardization) 11608-1 and Good Manufacturing Practice compliant laboratory. The average mass of wasted GH from each device type was measured in simulations of dripping with the needle attached prior to injection and while setting a dose. Statistical significance (P < 0.05) was confirmed by Student&#39;s t-test, and a model was constructed to estimate mean annual GH wastage per patient in cohorts of pediatric patients with GH disorders. Results: Mean GH mass wasted with the needle on prior to injection was 0.0 &micro;g with Norditropin pens, relative to 98 &micro;g with Omnitrope Pen-5. During dose dialing, 0.0&ndash;2.3 &micro;g of GH was lost with Norditropin pens versus 0.8 &micro;g with Omnitrope Pen-5. All Norditropin and Omnitrope device comparisons were statistically significant. Modeling GH wastage in a US cohort showed 5.5 mg of annual GH wastage per patient with FlexPro versus 43.6 mg with Omnitrope, corresponding to 7&ndash;8 additional pens per patient annually. Conclusion: Overall, Norditropin pens resulted in significantly less wastage than the Omnitrope Pen-5. The study suggests that GH devices of the same nominal volume exhibit differences that may affect the frequency of GH prescription refills required to remain adherent to therapy. Keywords: human growth hormone, administration, dosage, injections, subcutaneous, computer models